摘要：

(57) to a new use of the [summary] HMG-CoA reductase inhibitor is provided. In the present invention, the HMG-CoA reductase inhibitors, which via a mechanism other than to prevent the formation of oxidized LDL, it up-regulates the activity of endothelial cell nitric oxide synthase are found. As a consequence, HMG-CoA reductase inhibitors are useful in treating or preventing conditions resulting from the expression and / or activity abnormally low endothelial cell nitric oxide synthase. Such conditions include, renal disease state seizure pulmonary hypertension, ischemic, impotence, heart failure, hypoxia-induced, insulin deficiency, progressive, and movement disorder syndrome of the esophagus or stomach, and the like. Subjects that are believed to benefit primarily by such treatment, including non hypercholesterolemia and non hyperlipidemia, it is not necessary to eliminate hypercholesterolemia and hyperlipidemia.

展开